Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer
Key Points
Key Points
- This guideline focuses on patients with advanced, recurrent, or metastatic prostate cancer and noncastrate testosterone levels whose disease is not yet castration-resistant, including those with biochemical recurrence only.
- The future of noncastrate advanced, recurrent, or metastatic prostate cancer care is predicted to include highly personalized treatment plans based on advanced genetic testing, next generation imaging, and the availability of highly predictive biomarkers.
- This targeted update is driven by results from recent Phase III clinical trials (ARASENS, PEACE-1, ENZAMET, and ARCHES) and two recent meta-analyses.
Treatment
...reatmen...
...itial Treatmen...
...mmendation 1.0(Updated) Docetaxel, abiratero...
...IVATION THERAPY (ADT) PLUS DOCETAXEL...
...ion 1.1(Updated) For patients with metastat...
...ion 1.11(New) For patients with de novo metastat...
...mendation 1.15(New) For patients with de...
...on 1.16(New) The recommended regimen...
...ommendation 1.2(Updated) For patien...
...ecommendation 1.3(Updated) For patients with me...
...PLUS ABIRATERONE...
...commendation 1.4For patients with high-ris...
...1.5For patients with low-risk de novo m...
...tion 1.6The recommended regimen for...
...US ENZALUTAMIDE...
...tion 1.7(Updated) ADT plus enzalutamide shoul...
...n 1.8(Updated) The recommended regi...
...PLUS APALUTAMIDE...
...mendation 1.9ADT plus apalutamide should...
Recommendation 1.95(Updated) The rec...
Combination Therapi...
...mendation 2.1ADT plus abiraterone and pr...
...ation 2.2In resource-constrained se...
...rly Androgen Deprivatio...
...ecommendation 3.1Early (immediate) ADT may b...
...ttent Androgen Deprivation...
...dation 4.1Intermittent therapy may b...
...Initial Management of Noncastrate M...